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ÖZET
Amaç: Bu çalışmada metotreksat (MTX) ile tedavi olmuş 
ektopik gebelik olgularında ipsilateral tubal pasaj kontrolü 
yapılarak sonuçların değerlendirilmesi amaçlandı.
Gereç ve yöntem: Çalışmaya ektopik gebelik nedeniy-
le tek doz MTX tedavisi almış yaşları 21 ile 40 arasında 
değişmekte olan 30 hasta dahil edildi. Hastaların tümü 
hemodinamik  olarak  stabildi.  MTX  tedavisine  başlama-
dan  önceki  serum  beta  human  chorionic  gonadotropin 
(BhCG)  seviyeleri,  ultrasonografi  bulguları  kaydedildi. 
Serum BhCG düzeyleri negatif olduktan 6 ay sonra tubal 
pasaj kontrolü yapılan hastalar tedavi sonuçları ile tekrar 
değerlendirildi.
Bulgular: Çalışmaya alınan 30 olgunun yaş ortalaması 
30.6±4.4 yıl idi. Olguların BhCG düzeyleri 160 ile 10910 
IU/L  arasında  değişmekte  olup,  ortalaması  2387±2499 
IU/L idi. Kullandıkları MTX dozları 50 mg ile 100 mg ara-
sında değişmekte olup, ortalaması 67.7±13.5 mg idi. Ol-
guların 4’üne (%13.3) ek doz MTX uygulandı. Olguların 
3’üne (%10) tedavi sırasında gelişen tubal rüptür nede-
niyle laparotomi yapıldı. Tedaviden 6 ay sonra tubal pa-
saj kontrolü yapılan 27 olgunun, 22’sinin (%81.5) tubal 
pasajı açık, 5’inin (%18.5) kapalı bulundu. Tubal pasajı 
açık olan olgular ile kapalı olan olguların BhCG düzeyleri 
arasında istatistiksel olarak anlamlı bir farklılık bulunmadı 
(p>0.05).
Sonuç:  Rüptüre  olmamış  ektopik  gebeliklerde  uygula-
nacak medikal tedavi ile daha az tubal hasar meydana 
gelmekte, anesteziye ve cerrahiye ait morbidite azaltmak-
tadır.
Anahtar kelimeler: Ektopik gebelik, metotreksat, tubal 
pasaj
ABSTRACT
Objectives: In this study, it was aimed to evaluate the 
results of ipsilateral tubal passage control in the cases 
treated with methotrexate (MTX).
Materials  and  methods:  Totally  30  patients  aged  be-
tween 21 and 40 years who have received single dose 
MTX treatment due to ectopic pregnancy was included. 
All patients were as hemodynamically stabile. Serum beta 
human chorionic gonadotropin (BhCG) levels and ultra-
sonographic findings prior to the MTX treatment were re-
corded. Patients were re-evaluated 6 months after serum 
BhCG levels became negative for the outcome of treat-
ment.
Results: The mean age of the 30 cases was 30.6±4.4 
years. The BhCG levels of the cases was changing be-
tween 160 and 10910, their average is 2387±2499 IU/L. 
The MTX dose  was changing  between  50 to 100  mg, 
with average of 67.7±13.5 mg. Four (13.3%) of the cases 
received additional dose of MTX. Laparotomy was per-
formed in 3 (10%) cases due to tubal rupture developing 
during the treatment. Among 27 cases on whom the tubal 
passage control is made 6 months after the treatment, 
tubal passage was found to be open in 22 (81.5%) of the 
cases and closed in 5 (18.5%). There was no significant 
difference between the BhCG levels of cases with open 
and closed tubal passage (p>0.05).
Conclusion:  The  medical  treatment  to  be  applied  on 
non-ruptured ectopic pregnancies has many advantages. 
Less tubal damage occurs by the medical treatment, it de-
creases the morbidity for anesthesia and surgery. J Clin 
Exp Invest 2011; 2 (4): 400-403
Key words: Ectopic pregnancy, methotrexate, tubal pas-
sage
INTRODUCTION
The ectopic pregnancy is defined as the settlement 
of fertilized ovum outside the uterus, frequently at 
fallopian tubes.1 Together with the fact that abnor-
mal localization is at fallopian tube at 90%, more 
rarely  abdominal,  cervical,  ovarian,  interstitial,  in-N. Y. Görük ve ark. Tubal passage control 401
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traligamentous, heterotopic, multiple ectopic preg-
nancies can be observed.2 The ectopic pregnancy is 
an important reason for maternal mortality and mor-
bidity. However, by early establishment of ectopic 
pregnancy diagnosis with the help of contemporary 
diagnostic methods, the treatment modalities which 
are more conservative than before can be applied.
For this aim, the more frequently used agent 
has  become  methotrexate  (MTX). As  the  experi-
ences obtained with the medical treatment flourish, 
single dose treatment regimens have appeared for 
simplifying the treatment, increasing the harmony, 
decreasing the side effects and costs.3
The reproductive result after the ectopic preg-
nancy is generally evaluated with the determination 
of tubal opening with histerosalpingography (HSG), 
future pregnancy and ectopic pregnancy’s relapse 
rate. In this study, the ipsilateral tubal passage con-
trol has been done in cases treated with MTX, and 
their results have been evaluated.
MATERIALS AND METHODS 
Totally 30 cases which have been given medical 
treatment due to ectopic pregnancy diagnosis in a 
Training and Research Hospital Clinic of Obstetrics 
and Gynecology have been included to study con-
tent. To the patients, the ectopic pregnancy diagno-
sis has been established by applying anamnesis, 
gynecological  examination,  physical  examination, 
pregnancy test, ultrasonography (USG) and dilata-
tion and curettage (D&C). All patients have been in-
formed about their statuses, the risks that they have 
been told. To the patients in which findings in fa-
vors of rupture has not been determined and which 
have been stabile hemodynamically, the information 
on the treatment protocol has been given and their 
consents have been obtained and single dose MTX 
treatment has been started.
From all patients, before starting the treatment, 
serum BhCG, full blood count, kidney and liver func-
tion  tests  have  been  requested. The  serum  beta 
human  chorionic  gonadotropin  values  and  USG 
findings have been recorded. Then, MTX 50 mg/
m2 dose has been made as i.m. At the 4th day of 
the treatment, the serum BhCG values have been 
repeated. The increases in the serum BhCG con-
centration between the 1st and 4th days have been 
accepted as normal. Between the 4th and 7th day, 
in the patients in whose serum BhCG concentra-
tion there is 15% decrease, the single dose MTX 
treatment has been accepted as adequate. Then, till 
the levels have become indeterminable, the weekly 
BhCG  follow-ups  have  been  realized.  However, 
to the patients in which any increase in the serum 
BhCG concentration after this or a decrease under 
15% at the 7th day, the treatment protocol has been 
repeated.
The patients benefiting from the MTX treatment 
have been called for control after 6 months after 
their serum BhCG levels have reached to negative 
values. The gynaecological examination and trans-
vaginal USG have been realized. Their USG find-
ings have been recorded. The patients requesting 
the evaluation of the oviducts opening at the side 
where the ectopic pregnancy develops have been 
informed  about  this  issue.  In  the  direction  of  the 
patients’ preferences, the ipsilateral tubal passage 
controls have been made in 18 of them with diag-
nostic laparoscopy and in 9 of them with HSG.
When HSG is imaged, 10ml iodine has been 
given inside from cervix with hysterography tool in a 
way not passing the pressure of 180 mm Hg to the 
patient in dorsolithotomy position in the sterile envi-
ronment. Meanwhile, the patient has been brought 
to the neutral position, two units of spot film have 
been imaged, and the tubal opening has been con-
trolled.
To the cases to which the diagnostic laparos-
copy will be applied, information regarding the inter-
ventions to be applied and their complications have 
been given and their approvals have been obtained. 
The cases have been given the dorsolithotomy posi-
tion under the general anaesthesia and the bladder 
has been emptied with sterile foley catheter. The 
venter dermis, vulva and vagina have been cleaned 
with povidone iodine. The uterus elevator has been 
placed to cervix. The verres injection has been en-
tered while the patients have been at neutral posi-
tion. After the confirmation of peritoneal entrance, 
the abdomen has been inflated with carbon dioxide 
gas till the pressure of 15 mmHg. After the trochar 
insertion, the patient has been brought to trendelen-
burg position and the operation has been started. 
Uterus, oviducts, ovaries has been panoramically 
evaluated. 50 ml methylene blue has been given in-
side from cervix with rubin tube placed as transvagi-
nal and it has been observed whether transmission 
from oviducts is available or not.
The treatment results of these patients whose 
tubal opening control has been realized with diag-
nostic laparoscopy and HSG have been examined 
and evaluated prospectively.
Statistical analysis
For statistical analyses, NCSS (Number Cruncher 
Statistical  System)  2007&PASS  2008  Statistical N. Y. Görük ve ark. Tubal passage control 402
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Software  (Utah,  USA)  program  has  been  used. 
While evaluating the study data, in addition to the 
descriptive  statistical  methods  (Mean,  Standard 
deviation, frequency), Mann Whitney U test of the 
quantitative data has been used. In the comparison 
of the qualitative data, Fisher’s Exact Chi-Square 
test  has  been  used.  The  statistically  significance 
has been accepted at the level of p<0.05.
RESULTS
The  average  age  of  the  cases  was  30.63±4.36 
years. Twelve of the cases (40%) have experienced 
surgery previously. While 20 of the cases (66.7%) 
have not used contraception method, 6 of the cases 
(20%) use intrauterine device, 2 of the cases (6.7%) 
use tubal ligation and 1 of the cases (3.3%) uses 
depo-provera and oral contraceptives.
As the cases’ BhCG levels change between 160 
IU/L and 10910 IU/L, its average is 2387±2500 IU/L. 
As the MTX doses that they have used change be-
tween 50 mg and 100 mg, its average is 67.7±13.5 
mg.
While  the  bulk  dimension  of  6  of  the  cases 
(20%) is below 4 cm, 24 of them (80%) is between 4 
cm and 5.5 cm. Four of the cases (13.3%) received 
additional dose MTX. No significant difference was 
found in BhCG levels of the cases who received ad-
ditional dose MTX and who not received (p>0.05). 
Also no significant relationship was found between 
additional  MTX  treatment  and  bulk  dimension 
(p>0.05) (Table1).
Table  1.  Dilatation  and  curettage,  bulk  size,  additional 
treatment, laparotomy and tubal passage control
n %
D&C Executed 21 70.0
Not executed 9 30.0
Bulk size <4 cm 6 20.0
≥4-5.5 cm 24 80.0
Additional treatment Available 4 13.3
NA 26 86.7
Laparotomy Available 3 10.0
NA 27 90.0
Tubal passage control open 22 81.5
close 5 18.5
D&C: Dilatation and curettage 
It has been found that tubal passage of 22 of 
27 cases (81.5%) was open while tubal passage 
control was performed and 5 of them (18.5%) were 
closed. No significant difference was found in BhCG 
levels of the cases with open or closed tubal pas-
sage (p>0.05). Also, there was no significant rela-
tionship between tubal passage opening and bulk 
dimension (p>0.05) (Table 2).
Table 2. The evaluation of tubal passage control
Tubal passage control P
Open Close
hCG,
Mean±SD (Median)
1555±1464
 (922)
4589±4117
 (4354)
0.151
Bulk size,
 n (%)
<4 cm 3 (%13.6) 2 (%40.0) 0.221
≥4-5.5 cm 19 (%86.4) 3 (%60.0)
DISCUSSION
In the past ten years, the ectopic pregnancy inci-
dence has increased dramatically. The increase in 
the sexual inherited disease risk, ovulation induc-
tion, assisted reproductive techniques, tubal steril-
ization and more accurate diagnosis methods used 
in the diagnosis make think that the ectopic preg-
nancy incidence increases in fact.4
The anamnesis and physical examination de-
termine  the  patients  under  risk  and  increase  the 
possibility  of  determining  the  non-ruptured  ecto-
pic pregnancies. In the normal pregnancies, when 
Transvaginal USG and b-HCG levels go over 1000-
1500 IU/L, gestational sac can be observed.5 In 90% 
of the ectopic pregnancies, the evidences regarding 
the extrauterine pregnancy can be determined. The 
determination of yolk salk, embryo, cardiac activity 
together with a gestational sac outside uterus make 
the establishment of ectopic pregnancy diagnosis 
and require emergency action.6
Stovall et al. have published the results of MTX 
treatment in 100 patients and 50 of the 100 cases 
had  diagnosis  with  laparoscopy  and  50  of  them 
with  non-  laparoscopy  algorithm.  Full  resolution 
has realized in 96 patients between 14- 92 days. In 
four patients, due to tubal rupture, laparotomy has 
been required; in one case, at a late period such 
as 23rd day of the MTX application, a rupture has 
occurred. In five patients, fetal cardiac activity has 
been observed and in all of these, the treatment has 
become successful. In 49 of 58 patients (84%) to N. Y. Görük ve ark. Tubal passage control 403
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whom the HSG is applied in the advanced follow-
up, it has been shown that the ipsilateral oviducts 
are open.7
In study of Hajenius et al. have reported single 
sided tubal opening rate after the medical treatment 
of the ectopic pregnancy has been compared with 
the  conservative  laparoscopic  treatment.  The  tu-
bal opening rate at the ipsilateral side after medi-
cal treatment has been similar to the conservative 
laparoscopic  treatment  (linear  salpingotomy)  and 
between 60%-85%.8
Elito et al. have evaluated tubal transmission 
prospectively  with  HSG  in  the  ectopic  pregnancy 
cases to which conservative method has been ap-
plied as a follow-up or methotrexate treatment in 
2005. It has been found that the cases having start-
ing BhCG value>5000 IU/L have 12 times more risk 
for oviducts obstruction. However, no relation has 
been determined between the obstruction and ecto-
pic pregnancy bulk size.9
In this study, 6 months after the medical treat-
ment, in 27 cases, tubal opening control has been 
made. It has been researched whether ipsilateral 
oviducts are open or not with HSG. In a similar way 
to the rates in the literature, it has been found that 
22 of the cases (81.5%) has open similar sided ovi-
ducts and 5 of them (18.5%) has been closed. Be-
tween serum BhCG levels of the cases with open 
tubal passage and the cases with closed ones when 
they get diagnosis, a statistically significant differ-
ence was not found (Table 2). However, while the 
average BhCG value of the cases whose ipsilateral 
tubal passages are observed open is 922 IU/ ml, 
the average BhCG value has been found as 4354 
IU/ ml in the cases whose similar sided tubal pas-
sages are closed. We think, if the patient number 
being increased, a statistically significant difference 
can be obtained.
In conclusion, it has been suggested that, the 
aim at the ectopic pregnancy treatment is to pro-
tect the fertility rather than saving life. With this aim, 
MTX has been researched very commonly and it 
is at the first rank among the methods, which are 
alternative to the surgery treatment. The medical 
treatment decreases the morbidity belonging to the 
anaesthesia and surgery. The success rate and the 
future reproduction performance are similar to the 
ones to whom the surgery treatment has been ap-
plied.
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